Author:
Rae-Grant Alexander,Day Gregory S.,Marrie Ruth Ann,Rabinstein Alejandro,Cree Bruce A.C.,Gronseth Gary S.,Haboubi Michael,Halper June,Hosey Jonathan P.,Jones David E.,Lisak Robert,Pelletier Daniel,Potrebic Sonja,Sitcov Cynthia,Sommers Rick,Stachowiak Julie,Getchius Thomas S.D.,Merillat Shannon A.,Pringsheim Tamara
Abstract
ObjectiveTo review evidence on starting, switching, and stopping disease-modifying therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and progressive MS forms.MethodsRelevant, peer-reviewed research articles, systematic reviews, and abstracts were identified (MEDLINE, CENTRAL, EMBASE searched from inception to November 2016). Studies were rated using the therapeutic classification scheme. Prior published Cochrane reviews were also used.ResultsTwenty Cochrane reviews and an additional 73 full-text articles were selected for data extraction through an updated systematic review (completed November 2016). For people with RRMS, many DMTs are superior to placebo (annualized relapses rates [ARRs], new disease activity [new MRI T2 lesion burden], and in-study disease progression) (see summary and full text publications). For people with RRMS who experienced a relapse on interferon-β (IFN-β) or glatiramer acetate, alemtuzumab is more effective than IFN-β-1a 44 μg subcutaneous 3 times per week in reducing the ARR. For people with primary progressive MS, ocrelizumab is probably more effective than placebo (in-study disease progression). DMTs for MS have varying adverse effects. In people with CIS, glatiramer acetate and IFN-β-1a subcutaneous 3 times per week are more effective than placebo in decreasing risk of conversion to MS. Cladribine, immunoglobulins, IFN-β-1a 30 μg intramuscular weekly, IFN-β-1b subcutaneous alternate day, and teriflunomide are probably more effective than placebo in decreasing risk of conversion to MS. Suggestions for future research include studies considering comparative effectiveness, usefulness of high-efficacy treatment vs stepped-care protocols, and research into predictive biomarkers.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference41 articles.
1. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
2. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines: Table 1.
3. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
4. American Academy of Neurology. Clinical Practice Guideline Process Manual, 2011 ed. [online]. St. Paul: The American Academy of Neurology; 2011. Available at: aan.com/policy-and-guidelines/guidelines/about-guidelines2/. Accessed March 12, 2016.
5. Institute of Medicine; Eden J , Levit L , Berg A , Morton S , editors. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research. Washington, DC: National Academies Press; 2011.
Cited by
104 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献